Metabolomics: Integration of a new "omics" with clinical pharmacology

Clinical Pharmacology and Therapeutics

Volumn 94, Issue 5, 2013, Pages 547-551

  James, L P ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b ARKANSAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

16ALPHA HYDROXYPRASTERONE; 4BETA HYDROXYCHOLESTEROL; 6BETA HYDROXYHYDROCORTISONE; ACETYLSALICYLIC ACID; ACYLCARNITINE; ADENOSINE KINASE; AMINOTRANSFERASE; BIOLOGICAL MARKER; CHOLESTEROL DERIVATIVE; CYTOCHROME P450 3A4; GLUTATHIONE; HYDROCORTISONE; KETOCONAZOLE; MIDAZOLAM; PARACETAMOL; PRASTERONE; RIFAMPICIN; UNCLASSIFIED DRUG;

CHOLESTEROL BLOOD LEVEL; CLINICAL PHARMACOLOGY; DIET; DRUG CLEARANCE; DRUG EFFICACY; DRUG METABOLISM; DRUG OXIDATION; DRUG RESPONSE; DRUG SAFETY; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; FATTY ACID OXIDATION; GENETIC HETEROGENEITY; GENOTYPE; HUMAN; INTESTINE FLORA; MASS SPECTROMETRY; METABOLOMICS; NEPHROTOXICITY; NONHUMAN; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHARMACOMETABOLOMICS; PHENOTYPE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMS BIOLOGY; THROMBOCYTE AGGREGATION;

BIOLOGICAL MARKERS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; METABOLOMICS; PHARMACEUTICAL PREPARATIONS; PHARMACOLOGY, CLINICAL;

EID: 84886668782     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.166     Document Type: Review

References (19)

1. Nicholson, J.K., Buckingham, M.J. & Sadler, P.J. High resolution 1H n.m.r. studies of vertebrate blood and plasma. Biochem. J. 211, 605-615 (1983).
2. Mäkinen, V-P., Kangas, A.J., Soininen, P., Würtz, P., Groop, P-H. & Ala-Korpela, M. Metabolic phenotyping of diabetic nephropathy. Clin. Pharmacol. Ther. 94, 566-569 (2013).
3. Robertson, D.G. & Frevert, U. Metabolomics in drug discovery and development. Clin. Pharmacol. Ther. 559-561 (2013).
4. O'Connell, T.M. & Watkins, P.B. The application of metabonomics to predict drug-induced liver injury. Clin. Pharmacol. Ther. 88, 394-399 (2010).
5. Beger, R.D., Sun, J. & Schnackenberg, L.K. Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity. Toxicol. Appl. Pharmacol. 243, 154-166. (2010).
6. Kaddurah-Daouk, R. & Krishnan, K.R.R. Metabolomics: A global biochemical approach to the study of central nervous system diseases. Neuropsychopharmacology Rev. 34, 173-186 (2009).
7. Clayton, T.A., Baker, D., Lindon, J.C., Everett, J.R. & Nicholson, J.K. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc. Natl. Acad. Sci. USA 106, 14728-14733 (2009).
8. Li, H. & Jia, W. Cometabolism of microbes and host: Implications for drug metabolism and drug-induced toxicity. Clin. Pharmacol. Ther. 94, 574-581 (2013).
9. Shin, K-H., Choi, M.H., Lim, K.S., Yu, K-S., Jang, I-J. & Cho, J-Y. Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance. Clin. Pharmacol. Ther. 94, 601-609 (2013).
10. Lewis, J.P., Yerges-Armstrong, L.M., Ellero-Simatos, S., Georgiades, A., Kaddurah-Daouk, R. & Hankemeier, T. Integration of pharmacometabolomic and pharmacogenomic approaches reveals novel insights into antiplatelet therapy. Clin. Pharmacol. Ther. 94, 570-573 (2013).
11. Coen, M., Lenz, E.M., Nicholson, J.K., Wilson, I.D., Pognan, F. & Lindon, J.C. An integrated metabonomic investigation of acetaminophen toxicity in the mouse using NMR spectroscopy. Chem. Res. Toxicol. 295-303 (2003).
12. Soga, T. et al. Differential metabolomics reveals ophthalmic acid as an oxidative stress biomarker indicating hepatic glutathione consumption. J. Biol. Chem. 281, 16768-16776 (2006).
13. Schnackenberg, L.K. et al. Evaluations of the transsulfuration pathway in multiple liver toxicity studies. Toxicol. Appl. Pharmacol. 235, 25-32 (2009).
14. Mitchell, J.R., Jollow, D.J., Potter, W.Z., Gillette, J.R. & Brodie, B.B. Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. J. Pharmacol. Exp. Ther.187, 211-217 (1973).
15. Clayton, T.A. et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440, 1073-1077 (2006).
16. Chen, C., Krausz, K.W., Shah, Y.M., Idle, J.R. & Gonzalez, F.J. Serum metabolomics reveals irreversible inhibition of fatty acid β-oxidation through the suppression of PPAR-α activation as a contributing mechanism of acetaminophen-induced hepatotoxicity. Chem. Res. Toxicol. 22, 699-707 (2009).
17. Bhattacharyya, S. et al. Acylcarnitine profiles in acetaminophen toxicity in the mouse: Comparison to toxicity, metabolism and hepatocyte regeneration. Metabolites 3, 606-622 (2013).
18. Bhattacharyya, S. Serum acylcarnitines as potential biomarkers of acetaminophen toxicity in the pediatric population. Metabolomics 2, 45 (2013).
19. Nicolescu, A., Simionescu, N., Ursu, L., Deleanu, C. & Simionescu, B.C. The effect of therapeutic doses of paracetamol and aspirin on the NMR profile of urine at 400 mhz. Rev. Roum. Chim. 57, 653-658 (2012).